RxDoctor Payments Data

Jennifer Schriever, MD

Family Medicine · Sioux Falls, SDNPI 1013912120

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 85.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $1,495, more than ten times the $22 reported in 2019. Among family medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,361in general payments, 2019–2025

Across 36 payments — averaging $65.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boston Scientific$104
  • Rhythm Pharmaceuticals, Inc.$76
  • Lilly USA, LLC$69
  • Daiichi Sankyo Inc.$38
  • Merck$22
  • plus $30 from 2 others

What the payments were for

  • Consulting fees$1,27854%
  • Food & beverage$84336%
  • Education$24010%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,361 in reported general payments places this provider in the 90th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$23,724
Medicare patients
78
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$117,560
WegovySemaglutide52$69,636
MounjaroTirzepatide48$52,339
FarxigaDapagliflozin Propanediol14$11,855
JardianceEmpagliflozin12$7,917
Lisdexamfetamine Dimesylate25$4,660
Topiramate189$1,980
Scopolamine24$1,293
Bupropion XlBupropion Hcl30$1,292
Quetiapine Fumarate25$994
Metformin Hcl ErMetformin Hcl103$989
Levetiracetam24$951
Midodrine Hcl12$843
Phenytoin Sodium Extended12$567
Glycopyrrolate12$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$2,021$187,196147 claims
Lilly USA, LLCMounjaro$69$52,33948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →